Emerge market에 집중하겠다.
----------------
- Revenue of $6.9 Billion Grew 6% on a Comparable, Constant Currency Basis; 61% as Reported
- Non-GAAP Diluted EPS of $1.06; GAAP Diluted EPS of $0.77
- Adjusted Free Cash Flow of $1.8 Billion; GAAP Cash Flow from Operations of $1.8 Billion
Cardiac and Vascular Group
The Cardiac and Vascular Group (CVG) includes the Cardiac Rhythm & Heart Failure (CRHF) and Coronary & Structural Heart (CSH) divisions, as well as the Aortic & Peripheral Vascular (APV) division, which includes businesses from legacy Medtronic and businesses added through the January 2015 acquisition of Covidien. CVG worldwide revenue of $2.410 billion increased 7 percent, or 8 percent as reported. CVG revenue performance was driven by strong, balanced growth across all three divisions.
Minimally Invasive Therapies Group
The Minimally Invasive Therapies Group (MITG) includes the Surgical Solutions and the Patient Monitoring & Recovery (PMR) divisions. MITG contains most of the legacy Covidien business that was acquired in late January 2015 and therefore was not reported as part of legacy Medtronic in the third quarter of fiscal year 2015. MITG worldwide revenue of $2.291 billion increased 5 percent, a strong quarter for the group with Surgical Solutions growing above market and PMR growing at market
Restorative Therapies Group
The Restorative Therapies Group (RTG) includes the Spine, Neuromodulation, and Surgical Technologies divisions, as well as the Neurovascular division, which was added through the January 2015 acquisition of Covidien. RTG worldwide revenue of $1.759 billion increased 4 percent, or 7 percent as reported. Group results were driven by strong growth in Neurovascular and Surgical Technologies, offsetting declines in Spine and Neuromodulation.
Diabetes Group
The Diabetes Group includes the Intensive Insulin Management (IIM), Diabetes Service & Solutions (DSS), and Non-Intensive Diabetes Therapies (NDT) divisions. Diabetes Group worldwide revenue of $474 million increased 11 percent, or 6 percent as reported. The group had strong, broad-based performance across all three divisions
----------------
Investors are focusing on operating margin, a measure of profit, as a gauge of how well Medtronic is absorbing Covidien, which it acquired in January 2015 for nearly $50 billion.
Medtronic’s adjusted operating margin of 27.8% was slightly below expectations of 28%-to-28.5%, Denhoy said.
Medtronic’s net income rose to $1.10 billion in the third quarter, ended Jan. 29, from $977 million a year earlier.
Revenue rose to $6.93 billion, up 6% when adjusted for currency impacts and the Covidien acquisition, helped by higher sales of implanted heart rhythm devices and pacemakers.
----------------
----------------
----------------
----------------
----------------
| Market Cap (intraday)5: | 104.31B | | Enterprise Value (Mar 2, 2016)3: | 123.00B | | Trailing P/E (ttm, intraday): | 42.39 | | Forward P/E (fye Apr 24, 2017)1: | 15.26 | | PEG Ratio (5 yr expected)1: | 2.41 | | Price/Sales (ttm): | 4.21 | | Price/Book (mrq): | 2.08 | | Enterprise Value/Revenue (ttm)3: | 4.76 | | Enterprise Value/EBITDA (ttm)6: | 15.95 |
|
| Fiscal Year | | Fiscal Year Ends: | Apr 24 | | Most Recent Quarter (mrq): | Oct 30, 2015 |
|
| Profitability | | Profit Margin (ttm): | 8.97% | | Operating Margin (ttm): | 21.04% |
|
| Management Effectiveness | | Return on Assets (ttm): | 4.72% | | Return on Equity (ttm): | 6.46% |
|
| Income Statement | | Revenue (ttm): | 25.82B | | Revenue Per Share (ttm): | 19.72 | | Qtrly Revenue Growth (yoy): | 61.70% | | Gross Profit (ttm): | 13.95B | | EBITDA (ttm)6: | 7.71B | | Net Income Avl to Common (ttm): | 2.32B | | Diluted EPS (ttm): | 1.75 | | Qtrly Earnings Growth (yoy): | -37.20% |
|
| Balance Sheet | | Total Cash (mrq): | 17.23B | | Total Cash Per Share (mrq): | 12.25 | | Total Debt (mrq): | 35.92B | | Total Debt/Equity (mrq): | 68.72 | | Current Ratio (mrq): | 3.54 | | Book Value Per Share (mrq): | 37.17 |
|
| Cash Flow Statement | | Operating Cash Flow (ttm): | 5.77B | | Levered Free Cash Flow (ttm): | 3.43B |
|
